Cobimetinib (GDC-0973, XL518)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mitogen-activated protein kinase (MAPK/ERK) pathway regulates cell proliferation and survival.
• Mutations in the MAPK/ERK pathway are implicated in various cancers, presenting therapeutic targets.
• Targeted therapies like BRAF and MEK inhibitors are emerging for cancer treatment.

Purpose of the Study:

• To highlight the role of the MAPK/ERK pathway in tumorigenesis.
• To discuss the development and application of MEK inhibitors in cancer therapy.
• To introduce cobimetinib as a selective MEK1/2 inhibitor for malignant melanoma.

Main Methods:

• Review of clinical studies and drug approvals.
• Analysis of the efficacy of MEK inhibitors in metastatic cancer.
• Examination of cobimetinib's mechanism of action and clinical use.

Main Results:

• BRAF inhibitors have been clinically available since 2011.
• Cobimetinib is an oral, selective MEK1/2 inhibitor.
• Cobimetinib received EMA and FDA approval in 2015 for malignant melanoma treatment in combination with vemurafenib.

Conclusions:

• Targeting the MAPK/ERK pathway, particularly with MEK inhibitors like cobimetinib, is a viable strategy for cancer treatment.
• Combination therapy with BRAF and MEK inhibitors demonstrates clinical efficacy.
• Cobimetinib represents a significant advancement in the treatment of BRAF-mutated malignant melanoma.